Evidence-based best practices for EGFR T790M testing in lung cancer in Canada

Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors (tkis) are recommended as first-line systemic therapy for patients with non-small-cell lung cancer (nsclc) having mutations in the EGFR gene. Resistance to tkis eventually occurs in all nsclc patients treated with such drugs. In pati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Curr Oncol
Hlavní autoři: Stockley, T., Souza, C.A., Cheema, P.K., Melosky, B., Kamel-Reid, S., Tsao, M.S., Spatz, A., Karsan, A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Multimed Inc. 2018
Témata:
Practice Guideline
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5927787/
https://ncbi.nlm.nih.gov/pubmed/29719432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.4044
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky